

S3 Table. Univariate and multivariate analysis for progression-free survival and overall survival in the entire cohort (n=176)

Variable	PFS				OS			
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex (female vs. male)	0.82 (0.58-1.17)	0.271	-	-	0.73 (0.51-1.05)	0.093	-	-
Age (≥ 60 yr vs. < 60 yr)	0.70 (0.49-1.00)	0.051	-	-	1.01 (1.00-1.03)	0.146	-	-
EGFR (positive vs. negative)	0.87 (0.62-1.23)	0.425	-	-	0.62 (0.43-0.90)	0.011	0.63 (0.43-0.91)	0.014
ALK (positive vs. negative)	0.44 (0.19-1.01)	0.052	-	-	0.54 (0.22-1.33)	0.183	-	-
ROS1 (positive vs. negative)	0.68 (0.36-1.31)	0.249	-	-	0.74 (0.38-1.47)	0.392	-	-
PD-L1 (positive vs. negative)	0.99 (0.69-1.41)	0.949	-	-	1.34 (0.92-1.95)	0.122	-	-
No. of metastatic lesions (per 1 lesion)	1.09 (0.85-1.41)	0.497	-	-	1.09 (0.83-1.42)	0.531	-	-
Systemic therapy (TKI vs. no TKI)	1.32 (0.93-1.86)	0.122	-	-	1.51 (1.04-2.19)	0.031	1.27 (0.77-2.10)	0.356
RT site (bone vs. others)	1.22 (0.84-1.76)	0.304	-	-	1.01 (0.68-1.50)	0.962	-	-
EQD2 (≥ 43.9 Gy vs. < 43.9 Gy)	0.83 (0.59-1.18)	0.834	-	-	0.97 (0.67-1.41)	0.891	-	-
Oligometastatic disease state (Oligoprogression vs. oligometastasis)	1.86 (1.27-2.73)	0.002	-	-	1.52 (1.01-2.30)	0.045	1.49 (0.99-2.25)	0.056

ALK, anaplastic lymphoma receptor tyrosine kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; EQD2, equivalent doses in 2 Gy fractions; HR, hazard ratio; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; ROS1, c-ros oncogene 1; RT, radiotherapy; TKI, tyrosine kinase inhibitor.